Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|November 12, 2013
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trialThomas E Hutson, Vladimir Lesovoy, Salman Al-Shukri, et al.
BMC Cancer|April 29, 2014
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancerChandra P Belani, Nobuyuki Yamamoto, Igor M Bondarenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanomaJohn Fruehauf, Jose Lutzky, David McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II studyJoan H Schiller, Timothy Larson, S-H Ignatius Ou, et al.
Journal of Clinical Pharmacology|April 5, 2013
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysisBrian I Rini, May Garrett, Bill Poland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancerHope S Rugo, Alison T Stopeck, Anil A Joy, et al.
Targeted Oncology|March 6, 2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trialBrian I Rini, David I Quinn, Michael Baum, et al.
Journal of Microbiology (Seoul, Korea)|April 21, 2016
Novel nuclear targeting coiled-coil protein of Helicobacter pylori showing Ca(2+)-independent, Mg(2+)-dependent DNase I activityYoung Chul Kwon, Sinil Kim, Yong Seok Lee, et al.
The Lancet. Oncology|October 22, 2013
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialBrian I Rini, Bohuslav Melichar, Takeshi Ueda, et al.
Clinical Genitourinary Cancer|February 9, 2013
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinibBrian I Rini, Thibault de La Motte Rouge, Andrea L Harzstark, et al.
Pageof 6